Hydroxyurea to prevent brain injury in children with sickle cell disease (HU Prevent)-A randomized, placebo-controlled phase II feasibility/pilot study

被引：4

作者：

Casella, James F. ^{[1
]}

Furstenau, Dana K. ^{[1
]}

Adams, Robert J. ^{[2
]}

Brambilla, Donald J. ^{[3
]}

Lebensburger, Jeffrey D. ^{[4
]}

Fehr, James J. ^{[5
]}

Jordan, Lori C. ^{[6
]}

King, Allison A. ^{[7
,8
]}

Ichord, Rebecca N. ^{[9
]}

McKinstry, Robert C. ^{[10
]}

Kraut, Michael A. ^{[11
]}

Shaw, Dennis W. ^{[12
]}

White, Desiree A. ^{[13
]}

Whyte-Stewart, Donna A. ^{[14
]}

Avadhani, Radhika ^{[15
]}

Barron-Casella, Emily A. ^{[1
]}

Cannon, Alicia D. ^{[16
]}

Eaton, Cyd K. ^{[17
]}

Riekert, Kristin A. ^{[18
]}

Shay, Joanne E. ^{[19
]}

Smith-Seidel, Cynthia A. ^{[20
]}

Weiss, Diane C. ^{[1
]}

Ostapkovich, Noeleen D. ^{[15
]}

Vermillion, Krista ^{[21
]}

Treine, Kevin E. ^{[15
]}

Kingsbury, Claire E. ^{[1
]}

Strouse, John J. ^{[22
]}

Thompson, Richard E. ^{[23
]}

Hanley, Daniel F. ^{[15
]}

机构：

[1] Johns Hopkins Univ, Dept Pediat, Div Hematol, Sch Med, 720 Rutland Ave,Ross Res Bldg 1125, Baltimore, MD 21205 USA

[2] Med Univ South Carolina, Dept Neurol, Charleston, SC USA

[3] Res Triangle Inst RTI Int, Rockville, MD USA

[4] Univ Alabama Birmingham, Dept Pediat, Div Pediat Hematol Oncol, Birmingham, AL USA

[5] Stanford Univ Sch Med, Dept Anesthesiol Perioperat & Pain Med, Stanford, CA USA

[6] Vanderbilt Univ, Dept Pediat, Div Pediat Neurol, Med Ctr, Nashville, TN USA

[7] Washington Univ, Div Pediat Hematol Oncol, St Louis, MO USA

[8] St Louis Childrens Hosp, St Louis, MO USA

[9] Univ Penn, Childrens Hosp Philadelphia, Perelman Sch Med, Dept Neurol & Pediat, Philadelphia, PA USA

[10] Washington Univ, Mallinckrodt Inst Radiol, Sch Med, St Louis, MO USA

[11] Johns Hopkins Univ, Dept Radiol & Radiol Sci, Sch Med, Baltimore, MD USA

[12] Seattle Childrens Hosp, Dept Radiol, Seattle, WA USA

[13] Washington Univ St Louis, Dept Psychol & Brain Sci, St Louis, MO USA

[14] Food & Drug Adm FDA, Div Nonmalignant Hematol, Silver Spring, MD USA

[15] Johns Hopkins Univ, BIOS Clin Trials Coordinating Ctr, Dept Neurol & Neurosurg, Sch Med, Baltimore, MD USA

[16] Kennedy Krieger Inst, Dept Neuropsychol, Baltimore, MD USA

[17] Johns Hopkins Bayview, Biostat Epidemiol & Data Management Core, Med Ctr, Baltimore, MD USA

[18] Johns Hopkins Univ, Dept Med, Div Pulm & Crit Care Med, Sch Med, Baltimore, MD USA

[19] Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD USA

[20] Martinsburg Vet Affairs Med Ctr VAMC, Dept Psychol, Martinsburg, WV USA

[21] Vanderbilt Univ, Vanderbilt Inst Clin & Translat Res VICTR, Med Ctr, Nashville, TN USA

[22] Duke Univ, Dept Med & Pediat, Sch Med, Durham, NC USA

[23] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 10期

关键词：

YOUNG-CHILDREN; CONTROLLED-TRIAL; ANEMIA; TRANSFUSIONS; ASSOCIATION; MANAGEMENT; ANESTHESIA; EXPOSURE; AGE;

D O I：

10.1002/ajh.27423

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Central nervous system (CNS) injury is common in sickle cell disease (SCD) and occurs early in life. Hydroxyurea is safe and efficacious for treatment of SCD, but high-quality evidence from randomized trials to estimate its neuroprotective effect is scant. HU Prevent was a randomized (1:1), double-blind, phase II feasibility/pilot trial of dose-escalated hydroxyurea vs. placebo for the primary prevention of CNS injury in children with HbSS or HbS-beta(0)-thalassemia subtypes of SCD age 12-48 months with normal neurological examination, MRI of the brain, and cerebral blood flow velocity. We hypothesized that hydroxyurea would reduce by 50% the incidence of CNS injury. Two outcomes were compared: primary-a composite of silent cerebral infarction, elevated cerebral blood flow velocity, transient ischemic attack, or stroke; secondary-a weighted score estimating the risk of suffering the consequences of stroke (the Stroke Consequences Risk Score-SCRS), based on the same outcome events. Six participants were randomized to each group. One participant in the hydroxyurea group had a primary outcome vs. four in the placebo group (incidence rate ratio [90% CI] 0.216 [0.009, 1.66], p = .2914) (similar to 80% reduction in the hydroxyurea group). The mean SCRS score was 0.078 (SD 0.174) in the hydroxyurea group, 0.312 (SD 0.174) in the placebo group, p = .072, below the p-value of .10 often used to justify subsequent phase III investigations. Serious adverse events related to study procedures occurred in 3/41 MRIs performed, all related to sedation. These results suggest that hydroxyurea may have profound neuroprotective effect in children with SCD and support a definitive phase III study to encourage the early use of hydroxyurea in all infants with SCD.

引用

页码：1906 / 1916

页数：11

共 33 条

[1] Hydroxyurea Use in Young Children With Sickle Cell Anemia in New York State [J].

Anders, David G. ;

Tang, Fei ;

Ledneva, Tatania ;

Caggana, Michele ;

Green, Nancy S. ;

Wang, Ying ;

Sturman, Lawrence S. .

AMERICAN JOURNAL OF PREVENTIVE MEDICINE, 2016, 51 (01) :S31-S38

[2] A patient-centered medical home model for comprehensive sickle cell care in infants and young children [J].

Barriteau, Christina M. ;

Murdoch, Alexandra ;

Gallagher, Shannon J. ;

Thompson, Alexis A. .

PEDIATRIC BLOOD & CANCER, 2020, 67 (06)

[3] Safety of Deep Sedation in Young Children with Sickle Cell Disease: A Retrospective Cohort Study [J].

Belmont, Ami P. ;

Nossair, Fadi ;

Brambilla, Donald ;

Friedman, Marjorie ;

Boswinkel, Jan ;

Bradford, Andrea B. ;

Kwiatkowski, Janet L. .

JOURNAL OF PEDIATRICS, 2015, 166 (05) :1226-1232

[4] Developing a risk-based composite neurologic outcome for a trial of hydroxyurea in young children with sickle cell disease [J].

Casella, James F. ;

Adams, Robert J. ;

Brambilla, Donald J. ;

Strouse, John J. ;

Maier, Pia ;

Dlugash, Rachel ;

Avadhani, Radhika ;

Vermillion, Krista ;

Tonascia, James ;

Voeks, Jenifer H. ;

Hanley, Daniel F. ;

Thompson, Richard E. ;

Lehmann, Harold P. ;

Goldenberg, Neil A. ;

Hale, Gregory A. ;

Case, Connie M. Piccone ;

Manwani, Deepa G. ;

Callaghan, Michael U. ;

Sarnaik, Sharada A. ;

Kwiatkowski, Janet L. ;

Boswinkel, Jan P. ;

Ichord, Rebecca N. ;

Kalpatthi, Ram V. ;

Nickel, Robert S. ;

Heitmiller, Eugenie S. ;

Guerrera, Michael F. ;

Aygun, Banu ;

Park, Hyde ;

Green, Nancy S. ;

Fuh, Beng R. ;

Brown, Robert C. ;

Inusa, Baba P. D. ;

Rees, David C. ;

Thompson, Alexis A. ;

Jackson, Sherron M. ;

Kanter, Julie ;

Villella, Anthony D. ;

Bansal, Manisha M. ;

Telfer, Paul T. ;

Fixler, Jason M. ;

Kirby-Allen, Melanie ;

Vichinsky, Elliott P. ;

Neumayr, Lynne D. ;

Lebensburger, Jeffrey D. ;

Black, Lucien V. ;

Hsu, Lewis L. ;

Alvarez, Ofelia A. ;

Redding-Lallinger, Rupa C. ;

King, Allison A. ;

McKinstry, Robert C. .

CLINICAL TRIALS, 2019, 16 (01) :20-31

[5] Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell Anemia [J].

DeBaun, M. R. ;

Gordon, M. ;

McKinstry, R. C. ;

Noetzel, M. J. ;

White, D. A. ;

Sarnaik, S. A. ;

Meier, E. R. ;

Howard, T. H. ;

Majumdar, S. ;

Inusa, B. P. D. ;

Telfer, P. T. ;

Kirby-Allen, M. ;

McCavit, T. L. ;

Kamdem, A. ;

Airewele, G. ;

Woods, G. M. ;

Berman, B. ;

Panepinto, J. A. ;

Fuh, B. R. ;

Kwiatkowski, J. L. ;

King, A. A. ;

Fixler, J. M. ;

Rhodes, M. M. ;

Thompson, A. A. ;

Heiny, M. E. ;

Redding-Lallinger, R. C. ;

Kirkham, F. J. ;

Dixon, N. ;

Gonzalez, C. E. ;

Kalinyak, K. A. ;

Quinn, C. T. ;

Strouse, J. J. ;

Miller, J. P. ;

Lehmann, H. ;

Kraut, M. A. ;

Ball, W. S., Jr. ;

Hirtz, D. ;

Casella, J. F. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (08) :699-710

[6] Central nervous system complications and management in sickle cell disease [J].

DeBaun, Michael R. ;

Kirkham, Fenella J. .

BLOOD, 2016, 127 (07) :829-838

[7] Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of theSPINtrial [J].

Galadanci, Najibah A. ;

Abdullahi, Shehu U. ;

Ali Abubakar, Shehi ;

Wudil Jibir, Binta ;

Aminu, Hauwa ;

Tijjani, Aliyu ;

Abba, Muhammad S. ;

Tabari, Musa A. ;

Galadanci, Aisha ;

Borodo, Auwal ;

Belonwu, Raymond ;

Salihu, Auwal S. ;

Rodeghier, Mark ;

Ghafuri, Djamila L. ;

Greene, Brittany V. Covert C. ;

Neville, Kathleen ;

Kassim, Adetola A. ;

Kirkham, Fenella J. ;

Jordan, Lori C. ;

Aliyu, Muktar H. ;

DeBaun, Michael R. .

AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (09) :E247-E250

[8] Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea [J].

Hankins, Jane S. ;

Helton, Kathleen J. ;

McCarville, M. Beth ;

Li, Chin-Shang ;

Wang, Winfred C. ;

Ware, Russell E. .

PEDIATRIC BLOOD & CANCER, 2008, 50 (02) :293-297

[9] Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study [J].

Hankins, JS ;

Ware, RE ;

Rogers, ZR ;

Wynn, LW ;

Lane, PA ;

Scott, JP ;

Wang, WC .

BLOOD, 2005, 106 (07) :2269-2275

[10] Age at Exposure to Surgery and Anesthesia in Children and Association With Mental Disorder Diagnosis [J].

Ing, Caleb ;

Sun, Ming ;

Olfson, Mark ;

DiMaggio, Charles J. ;

Sun, Lena S. ;

Wall, Melanie M. ;

Li, Guohua .

ANESTHESIA AND ANALGESIA, 2017, 125 (06) :1988-1998

← 1 2 3 4 →